<prompt> A 56-year-old man is diagnosed with the metabolic syndrome, which consists of hypertension, insulin resistance, dyslipidemia, and abdominal obesity. He has no prior history of cardiac or vascular disease and is otherwise well. His fasting T-chol is 270 mgdL, HDL 50 mgdL, LDL 150 mgdL, and triglycerides 150 mgdL. His Framingham risk calculation approximates a 10- year risk for cardiac events of 10-20.For the above patient with dyslipidemia, select the most appropriate treatment.fibric acid derivatives clofibrate, gemfibrozilnicotinic acidbile acid-binding resins cholestyramine, colestipolhepatic hydroxymethylglutaryl coenzyme A HMG-Co reductase inhibitors lovastatin, simvastatin, pravastatin  <response>: The metabolic syndrome is frequently identified among individuals given the increasing rates of obesity and diabetes in Western society. This individual has multiple atherogenic risk factors obesity, hypertension, increased LDL and his 10-year risk for cardiac events is approximated at 10-20 by the risk calculator. At this risk level, the LDL goal is 130 mgdL and treatment threshold for starting drug therapy is 130 mgdL. Lifestyle modification too is an important component of the overall treatment. 